Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling
Abstract Background KRASG12C inhibitors (KRASG12Ci) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRASG12C-mutant cancers. However, the emergence of therapy-related drug resistance limits their long-term potential. This study aimed to iden...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-023-00466-3 |
| _version_ | 1797388481320714240 |
|---|---|
| author | Yafang Wang Mingyue Yao Cheng Li Kexin Yang Xiaolong Qin Lansong Xu Shangxuan Shi Chengcheng Yu Xiangjun Meng Chengying Xie |
| author_facet | Yafang Wang Mingyue Yao Cheng Li Kexin Yang Xiaolong Qin Lansong Xu Shangxuan Shi Chengcheng Yu Xiangjun Meng Chengying Xie |
| author_sort | Yafang Wang |
| collection | DOAJ |
| description | Abstract Background KRASG12C inhibitors (KRASG12Ci) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRASG12C-mutant cancers. However, the emergence of therapy-related drug resistance limits their long-term potential. This study aimed to identify the critical mediators and develop overcoming strategies. Methods By using RNA sequencing, RT-qPCR and immunoblotting, we identified and validated the upregulation of c-Myc activity and the amplification of the long noncoding RNA ST8SIA6-AS1 in KRASG12Ci-resistant cells. The regulatory axis ST8SIA6-AS1/Polo-like kinase 1 (PLK1)/c-Myc was investigated by bioinformatics, RNA fluorescence in situ hybridization, RNA immunoprecipitation, RNA pull-down and chromatin immunoprecipitation. Gain/loss-of-function assays, cell viability assay, xenograft models, and IHC staining were conducted to evaluate the anti-cancer effects of co-inhibition of ST8SIA6-AS1/PLK1 pathway and KRAS both in vitro and in vivo. Results KRASG12Ci sustainably decreased c-Myc levels in responsive cell lines but not in cell lines with intrinsic or acquired resistance to KRASG12Ci. PLK1 activation contributed to this ERK-independent c-Myc stability, which in turn directly induced PLK1 transcription, forming a positive feedback loop and conferring resistance to KRASG12Ci. ST8SIA6-AS1 was found significantly upregulated in resistant cells and facilitated the proliferation of KRASG12C-mutant cancers. ST8SIA6-AS1 bound to Aurora kinase A (Aurora A)/PLK1 and promoted Aurora A-mediated PLK1 phosphorylation. Concurrent targeting of KRAS and ST8SIA6-AS1/PLK1 signaling suppressed both ERK-dependent and -independent c-Myc expression, synergistically led to cell death and tumor regression and overcame KRASG12Ci resistance. Conclusions Our study deciphers that the axis of ST8SIA6-AS1/PLK1/c-Myc confers both intrinsic and acquired resistance to KRASG12Ci and represents a promising therapeutic target for combination strategies with KRASG12Ci in the treatment of KRASG12C-mutant cancers. |
| first_indexed | 2024-03-08T22:41:27Z |
| format | Article |
| id | doaj.art-81b034e470a54bacb2a8bc9ea154a2fa |
| institution | Directory Open Access Journal |
| issn | 2162-3619 |
| language | English |
| last_indexed | 2024-03-08T22:41:27Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj.art-81b034e470a54bacb2a8bc9ea154a2fa2023-12-17T12:09:13ZengBMCExperimental Hematology & Oncology2162-36192023-12-0112112210.1186/s40164-023-00466-3Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signalingYafang Wang0Mingyue Yao1Cheng Li2Kexin Yang3Xiaolong Qin4Lansong Xu5Shangxuan Shi6Chengcheng Yu7Xiangjun Meng8Chengying Xie9Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversitySchool of Life Science and Technology, ShanghaiTech UniversityShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityDrug Discovery and Development Center, Shanghai Institute of Materia Medica, Chinese Academy of SciencesGastroenterology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of MedicineShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech UniversityAbstract Background KRASG12C inhibitors (KRASG12Ci) AMG510 and MRTX849 have shown promising efficacy in clinical trials and been approved for the treatment of KRASG12C-mutant cancers. However, the emergence of therapy-related drug resistance limits their long-term potential. This study aimed to identify the critical mediators and develop overcoming strategies. Methods By using RNA sequencing, RT-qPCR and immunoblotting, we identified and validated the upregulation of c-Myc activity and the amplification of the long noncoding RNA ST8SIA6-AS1 in KRASG12Ci-resistant cells. The regulatory axis ST8SIA6-AS1/Polo-like kinase 1 (PLK1)/c-Myc was investigated by bioinformatics, RNA fluorescence in situ hybridization, RNA immunoprecipitation, RNA pull-down and chromatin immunoprecipitation. Gain/loss-of-function assays, cell viability assay, xenograft models, and IHC staining were conducted to evaluate the anti-cancer effects of co-inhibition of ST8SIA6-AS1/PLK1 pathway and KRAS both in vitro and in vivo. Results KRASG12Ci sustainably decreased c-Myc levels in responsive cell lines but not in cell lines with intrinsic or acquired resistance to KRASG12Ci. PLK1 activation contributed to this ERK-independent c-Myc stability, which in turn directly induced PLK1 transcription, forming a positive feedback loop and conferring resistance to KRASG12Ci. ST8SIA6-AS1 was found significantly upregulated in resistant cells and facilitated the proliferation of KRASG12C-mutant cancers. ST8SIA6-AS1 bound to Aurora kinase A (Aurora A)/PLK1 and promoted Aurora A-mediated PLK1 phosphorylation. Concurrent targeting of KRAS and ST8SIA6-AS1/PLK1 signaling suppressed both ERK-dependent and -independent c-Myc expression, synergistically led to cell death and tumor regression and overcame KRASG12Ci resistance. Conclusions Our study deciphers that the axis of ST8SIA6-AS1/PLK1/c-Myc confers both intrinsic and acquired resistance to KRASG12Ci and represents a promising therapeutic target for combination strategies with KRASG12Ci in the treatment of KRASG12C-mutant cancers.https://doi.org/10.1186/s40164-023-00466-3KRASG12Cc-MycPLK1LncRNAST8SIA6-AS1Drug resistance |
| spellingShingle | Yafang Wang Mingyue Yao Cheng Li Kexin Yang Xiaolong Qin Lansong Xu Shangxuan Shi Chengcheng Yu Xiangjun Meng Chengying Xie Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling Experimental Hematology & Oncology KRASG12C c-Myc PLK1 LncRNA ST8SIA6-AS1 Drug resistance |
| title | Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling |
| title_full | Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling |
| title_fullStr | Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling |
| title_full_unstemmed | Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling |
| title_short | Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling |
| title_sort | targeting st8sia6 as1 counteracts krasg12c inhibitor resistance through abolishing the reciprocal activation of plk1 c myc signaling |
| topic | KRASG12C c-Myc PLK1 LncRNA ST8SIA6-AS1 Drug resistance |
| url | https://doi.org/10.1186/s40164-023-00466-3 |
| work_keys_str_mv | AT yafangwang targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT mingyueyao targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT chengli targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT kexinyang targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT xiaolongqin targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT lansongxu targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT shangxuanshi targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT chengchengyu targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT xiangjunmeng targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling AT chengyingxie targetingst8sia6as1counteractskrasg12cinhibitorresistancethroughabolishingthereciprocalactivationofplk1cmycsignaling |